Education
About Us
Working with TipRanks
Follow Us
ObsEva (OBSEF)
OTHER OTC:OBSEF
OBSEF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume1.40K
Average Volume (3M)150.00
Market Cap
$11.72K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta14.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding117,177,284
10 Day Avg. Volume150
30 Day Avg. Volume150
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
OBSEF FAQ
What was ObsEva’s price range in the past 12 months?
ObsEva lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is ObsEva’s market cap?
ObsEva’s market cap is $11.72K.
When is ObsEva’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ObsEva’s earnings last quarter?
Currently, no data Available
Is ObsEva overvalued?
According to Wall Street analysts ObsEva’s price is currently Overvalued.
Does ObsEva pay dividends?
ObsEva does not currently pay dividends.
What is ObsEva’s EPS estimate?
ObsEva’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ObsEva have?
ObsEva has 117,177,284 shares outstanding.
What happened to ObsEva’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ObsEva?
Currently, no hedge funds are holding shares in OBSEF
Company Description
ObsEva
ObsEva SA engages in the development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
TNF Pharmaceuticals
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Oragenics
―
Onconetix
―